{"id":7046,"date":"2025-10-08T15:22:58","date_gmt":"2025-10-08T19:22:58","guid":{"rendered":"https:\/\/cqdm.org\/?post_type=project&p=7046"},"modified":"2025-10-08T15:28:32","modified_gmt":"2025-10-08T19:28:32","slug":"preclinical-development-of-a-pseudomonas-aeruginosa-vaccine","status":"publish","type":"project","link":"https:\/\/cqdm.org\/en\/achievement\/funded-projects\/preclinical-development-of-a-pseudomonas-aeruginosa-vaccine\/","title":{"rendered":"Preclinical development of a Pseudomonas aeruginosa vaccine"},"content":{"rendered":"\n
\n
\n

Principal Investigator<\/strong><\/p>\n\n\n\n

M\u00e9lanie Arbour<\/strong>
CNRC<\/p>\n<\/div>\n\n\n\n

\n

Co-investigator<\/strong><\/p>\n\n\n\n

Wangxue Chen
<\/b><\/span>CNRC<\/p>\n\n\n\n

Fran\u00e7ois Meurens
<\/b><\/span>Universit\u00e9 de Montr\u00e9al<\/p>\n\n\n\n

Fanny Renois
<\/b><\/span>Universit\u00e9 de Montr\u00e9al<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n\n\n\n

Project of <\/span>$1,133,677<\/strong><\/strong> over 3 years<\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/h2>\n\n\n\n
    \n
  • Supported by CQDM through:<\/strong><\/strong>
    Minist\u00e8re de l\u2019\u00c9conomie, de l\u2019Innovation et de l\u2019\u00c9nergie du Qu\u00e9bec (MEIE)<\/li>\n\n\n\n
  • And by co-funding partner:<\/strong><\/strong><\/strong>
    – Glycovax Pharma inc.<\/li>\n<\/ul>\n\n\n\n
    \n\n\n\n

    Challenge<\/h3>\n\n\n\n

    Pseudomonas aeruginosa<\/em> (Pa<\/em>) is a multidrug-resistant bacterium and ESKAPE pathogen responsible for nosocomial infections and a predominant cause of morbidity and mortality in cystic fibrosis patients. No vaccine is yet available to prevent Pa<\/em> infections.<\/p>\n\n\n\n

    Solution<\/h3>\n\n\n\n

    The NRC has identified a vaccine antigen in the Pa bacterium’s type A liposaccharide that is common to several clinical strains. Specifically, the antigen identified is a methylated rhamnan oligosaccharide, which when conjugated to the CRM197 carrier protein proved immunogenic and antigenic in both mice and rabbits. Glycovax and the NRC are planning to develop a vaccine based on this glycoantigen and the novel adjuvant SLA, which was also designed by the NRC. The candidate vaccine contains two vaccine components, SLA and CRM197, which Glycovax is manufacturing for commercialization. Development activities will consist of proof-of-concept studies in animals with selection of the optimal vaccine composition, formulation and route of administration in mice. The functional efficacy of vaccination against a Pa infection will then be demonstrated by quantifying protection in translational studies using a large animal model such as the pig at the veterinary school of Universit\u00e9 de Montr\u00e9al.<\/p>\n\n\n\n

    Expected Achievements\/Impact<\/h3>\n\n\n\n

    Establishing the vaccine composition and its preliminary efficacy by translational studies in new animal models of Pa infection is the first step towards clinical trials. A Pa vaccine available to cystic fibrosis patients and people entering hospitals at risk of nosocomial infection will be a real public-health breakthrough. The project will train young professionals in Quebec in animal models of bacterial infection, as well as in the specific regulatory stages of vaccine development, where the latter expertise is directly applicable to the development of other new vaccines.<\/p>\n","protected":false},"featured_media":3823,"template":"","project-category":[97],"class_list":["post-7046","project","type-project","status-publish","has-post-thumbnail","hentry","project-category-biological-and-therapeutic"],"acf":[],"_links":{"self":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project\/7046","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/types\/project"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media\/3823"}],"wp:attachment":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media?parent=7046"}],"wp:term":[{"taxonomy":"project-category","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project-category?post=7046"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}